The market expects Viatris (VTRS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 9, 2024, might help the stock move higher if these key numbers are better th ...

PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international ...

PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific bac ...

Vertigo3d There is quite a pronounced valuation gap in the pharmaceuticals sector, with richly priced names like Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) on the high-end of the spectrum, and others like Bristol Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD) on the other end. This brings me to the even lower-priced name, Viatris Inc. (NASDAQ:VTRS) which falls in the deep value category. I last covered VTRS back in June of last year, noting that it wouldn't take much to move the nee ...

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States. RYZUMVI is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.1 According to the American Academy of Op ...

Viatris (VTRS -1.45%) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around generic drugs. But while its operations are diverse, this isn't the type of enterprise that screams growth. Chances are, if you're considering Viatris for your portfolio, it's because of its dividend and low valuation.With a 3.9% yield, the healthcare stock offers investors a higher payout than the S&P 500 average of 1. ...

Shares of Viatris, Inc. (VTRS) lost 4.8% in the last three trading sessions after the company reported lower-than-expected fourth-quarter results on Feb 28, before market open.Fourth-quarter 2023 adjusted earnings of 61 cents per share missed the Zacks Consensus Estimate of 67 cents.Total revenues came in at $3.8 billion, up 1% year over year on a divestiture-adjusted operational basis. However, the top line missed the Zacks Consensus Estimate of $3.9 million.Branded business grew 3%, driven by brands like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. ...

Financial Data and Key Metrics Changes - In 2023, the company reported total revenues of approximately $15.4 billion, adjusted EBITDA of approximately $5.1 billion, and free cash flow of approximately $2.4 billion [36][46][62] - The adjusted gross margin for the full year was at 59.1%, driven by strong brand performance [43] - The company anticipates total revenue growth of approximately 2% for 2024, with new product revenue expected to be between $450 million to $550 million [3][52] Business Line Data and Key Metrics Changes - The Greater China segment delivered 2% growth in 2023, primarily due to strong retail performance [1] - The JANZ segment is expected to decline by 8% in 2024 due to government-driven price regulations [2] - Developed Markets saw a 1% decline in 2023, but growth is expected to return in 2024 with both Europe and North America projected to grow by 3% [4][5] - The Eye Care portfolio is expected to see further gains in 2024, driven by prescription growth in Tyrvaya and the launch of Ryzumvi [7] Market Data and Key Metrics Changes - Emerging Markets achieved 7% year-over-year operational growth in 2023, with projections of 6% growth in 2024 [8] - The company noted strong performance in markets such as Turkey, South Korea, and Southeast Asia [8] Company Strategy and Development Direction - The company aims to leverage investments to expand the self-pay patient market and brand equity, anticipating a 2% year-over-year decline in 2024 due to healthcare policy regulations [18] - A global research and development collaboration with Idorsia was announced, focusing on two late-stage potential blockbuster assets [26][37] - The company is committed to maintaining a balanced capital allocation approach, including share repurchases and dividends while investing in future growth [24][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the core business and the potential for continued growth into 2024 and beyond [16][27] - The company expects to generate approximately $2.5 billion in free cash flow in 2024 before any divestiture costs and taxes [53] - Management highlighted the importance of finding impactful assets that can drive long-term revenue streams [72] Other Important Information - The company completed $250 million in share repurchases earlier in the year and has an additional $1 billion share repurchase authorization [28] - The anticipated driver for adjusted EBITDA includes contributions from new product launches and revenue growth, with an estimated impact from remaining divestitures [53][56] Q&A Session Summary Question: Follow-up on business development strategy - Management indicated that finding impactful assets is challenging, but building a commercial structure around them is easier if the asset is impactful [72] Question: Thoughts on the Eye Care franchise and commercial launch of Ryzumvi - Management noted that the DTC campaign for Tyrvaya has shown an 18% increase in prescriptions, and they are optimistic about the upcoming launch of Ryzumvi [112] Question: Insights on the FTC examination regarding PBMs and wholesaler practices - Management observed stabilization in pricing and emphasized the industry's shift towards quality and availability rather than just cost [120] Question: Differentiation of Selatogrel and Cenerimod - Management highlighted that Selatogrel targets a critical time in heart attack treatment where no current treatment exists, while Cenerimod shows strong Phase 2 data and fast track designation [104][105] Question: Philosophical approach to business development - Management stated that they will consider a wide range of opportunities, including licensing and partnerships, while focusing on building a strong portfolio [124]

Viatris Inc. (VTRS) delivered adjusted earnings of 61 cents per share in the fourth quarter of 2023, missing the Zacks Consensus Estimate of 67 cents. The company recorded adjusted earnings of 67 cents in the year-ago quarter.Total revenues came in at $3.8 billion, up 1% year over year on a divestiture-adjusted operational basis. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.9 million.Viatris’ stock has declined in the premarket due to the disappoi ...